N/A
N=166
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
Herpes Zoster
Bottom Line
View on ClinicalTrials.gov: NCT01483378 ↗Enrolled (actual)
166
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcome: Primary: Answers to Survey Questions — 89; 71.2; 98; 74 Percentage of responders
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Choosing to receive the vaccine (Other)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- NYU Langone Health
- Primary completion
- Feb 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Answers to Survey Questions |
89; 71.2; 98; 74 | — |
Summary
The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse administer the vaccine in the General Eye Clinic.
Eligibility Criteria
Inclusion Criteria
- 60 years of age or older
- Absence of evidence of immune compromise in the medical record
- Ability to speak and read English, Spanish or Chinese and give informed consent
Exclusion Criteria
- Vulnerable patients, including the cognitively impaired, prisoners and employee
- FDA contraindications for Zostavax vaccine
Data sourced from ClinicalTrials.gov (NCT01483378). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.